These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30896643)

  • 1. Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension.
    Zhang JQ; Yang GH; Zhou X; Liu JX; Shi R; Dong Y; Chen SB; Li YM
    Medicine (Baltimore); 2019 Mar; 98(12):e14907. PubMed ID: 30896643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk.
    Li Y; Li XH; Huang ZJ; Yang GP; Zhang GG; Zhao SP; Guo Y; Lu SJ; Ma JL; Meng FB; Chen P; Yuan H
    PLoS One; 2015; 10(2):e0117560. PubMed ID: 25693004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial.
    Zhang G; Fan Y; Qiu Y; Zhou Z; Zhang J; Wang Z; Liu Y; Liu X; Tao J
    Adv Ther; 2020 Aug; 37(8):3551-3561. PubMed ID: 32583313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension.
    Wang H; Xi Y; Chen Y; Wang L; Yang F; Lu X; Sun N
    Am J Hypertens; 2023 Sep; 36(10):561-567. PubMed ID: 37343187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of allisartan-isoproxil-based combination antihypertensive regimen in hypertensive patients with microalbuminuria or hyperuricemia.
    Sun N; Wang H
    J Clin Hypertens (Greenwich); 2024 Mar; 26(3):241-250. PubMed ID: 38319613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage.
    Ling QS; Zhang SL; Tian JS; Cheng MH; Liu AJ; Fu FH; Liu JG; Miao CY
    Acta Pharmacol Sin; 2021 Jun; 42(6):871-884. PubMed ID: 34002042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allisartan ameliorates vascular remodeling through regulation of voltage-gated potassium channels in hypertensive rats.
    Zhang X; Zhao Z; Xu C; Zhao F; Yan Z
    BMC Pharmacol Toxicol; 2021 Jun; 22(1):33. PubMed ID: 34108047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
    Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.
    Weir MR; Elkins M; Liss C; Vrecenak AJ; Barr E; Edelman JM
    Clin Ther; 1996; 18(3):411-28. PubMed ID: 8829017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study.
    Zhang J; Zhang W; Yan J; Ge Q; Lu XH; Chen SX; Xu WJ; Li Y; Li JF; He SY; Wang JG
    Hypertens Res; 2023 Aug; 46(8):2024-2032. PubMed ID: 37258625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allisartan isoproxil attenuates oxidative stress and inflammation through the SIRT1/Nrf2/NF‑κB signalling pathway in diabetic cardiomyopathy rats.
    Jin Q; Zhu Q; Wang K; Chen M; Li X
    Mol Med Rep; 2021 Mar; 23(3):. PubMed ID: 33495841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis.
    Zhao F; Liu Y; Chen L
    Front Cardiovasc Med; 2024; 11():1355014. PubMed ID: 38903964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study.
    Jekell A; Malmqvist K; Wallén NH; Mörtsell D; Kahan T
    J Cardiovasc Pharmacol; 2013 Dec; 62(6):559-66. PubMed ID: 24084214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension.
    Ikeda LS; Harm SC; Arcuri KE; Goldberg AI; Sweet CS
    Blood Press; 1997 Jan; 6(1):35-43. PubMed ID: 9116924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis.
    Liu J; Chen W; Shao S; Chen Y; Wang H; Xi Y; Wang L
    Ann Med; 2024 Dec; 56(1):2362880. PubMed ID: 38830046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early intervention of long-acting nifedipine GITS reduces brachial-ankle pulse wave velocity and improves arterial stiffness in Chinese patients with mild hypertension: a 24-week, single-arm, open-label, prospective study.
    Zhang J; Wang Y; Hu H; Yang X; Tian Z; Liu D; Gu G; Zheng H; Xie R; Cui W
    Drug Des Devel Ther; 2016; 10():3399-3406. PubMed ID: 27799740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of doxazosin mesylate versus nifedipine on blood pressure variability in hypertensive patients: a randomized crossover study (SIMILAR).
    Shi J; Liang D; Pan Y; Zhang S; He M; Zhang H; Liu G; Gong Y; Wang W; Cang H; Li Y
    Blood Press Monit; 2019 Oct; 24(5):252-258. PubMed ID: 31116151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reverse remodeling and improved function by antihypertensive treatment in hypertensive patients with coronary artery disease.
    Yui Y; Kodama K; Hirayama A; Nishio R; Iwanaga Y; Nonogi H; Haze K; Sumiyoshi T; Yui N; Hosoda S; Kawai C;
    J Hypertens; 2010 Jan; 28(1):178-85. PubMed ID: 19927011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial.
    Kang MG; Kim KI; Ihm SH; Rhee MY; Sohn IS; Lee HY; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
    Trials; 2019 Jul; 20(1):389. PubMed ID: 31262348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.